11 completed, 5 recruiting, 4 active not recruiting, 4 not yet recruiting. 11 Phase 2, 10 Phase 1, 5 Phase 3, 2 Not applicable.
Follow Advanced Ovarian Cancer: new trials by email Literature Review of Advanced Ovarian Cancer trials Research Report on Advanced Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer AST-201, Paclitaxel, Carboplatin - Advanced Ovarian Cancer | Phase 2 | Not yet recruiting | Aston Sci. Inc. | 98 | 2027-06-01 | 2026-10-27 |
| Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker Senaparib, Bevacizumab - Advanced Ovarian Cancer | Phase 2 | Not yet recruiting | Fudan University | 37 | 2025-10-10 | 2025-08-13 |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors BMS-986500, Palbociclib, Fulvestrant - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | Bristol-Myers Squibb | 234 | 2025-08-01 | 2026-10-06 |
| Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer Zejula (Niraparib) - Advanced Ovarian Cancer | Not yet recruiting | Clinica Universidad de Navarra, Universidad de Navarra | 120 | 2025-07-25 | 2025-07-11 | |
| Centralization and Oncologic Outcomes in Ovarian Cancer No Intervention: Observational Cohort - Epithelial Ovarian Cancer, Ovarian Neoplasms | Recruiting | Azienda USL Reggio Emilia - IRCCS | 200 | 2025-06-27 | 2026-07-24 | |
| SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT), Cadonilimab - Advanced Gastric Cancer, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | Zhang Tao | 26 | 2025-03-20 | 2025-04-27 |
| Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Recruiting | Anhui Provincial Hospital | 100 | 2025-03-11 | 2026-10-28 |
| A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha MOv18 IgE - Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 1 | Recruiting | Epsilogen Ltd | 45 | 2024-09-03 | 2026-04-06 |
| Plasmodium Immunotherapy for Advanced Ovarian Cancer Plasmodium immunotherapy - Advanced Ovarian Cancer | Phase 2 / Phase 3 | Not yet recruiting | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | 30 | 2024-07-20 | 2024-07-22 |
| SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer SC0191, Gemcitabine, Paclitaxel - Serous Ovarian Cancer, Advanced Ovarian Cancer | Phase 1 / Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 112 | 2023-10-30 | 2023-09-26 |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer None (Observational Study) - Advanced Ovarian Cancer | Completed | AstraZeneca | 24 | 2023-07-10 | 2024-09-20 | |
| Bioequivalence Study of Liposomal Doxorubicin 20 mg/10 mL (Doxopeg® vs Caelyx®) in Advanced Cancer Patients Doxopeg® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL), Caelyx® - Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) - Advanced Ovarian Cancer, Metastatic Breast Cancer | Phase 1 | Completed | Zodiac Produtos Farmaceuticos S.A. | 74 | 2023-02-13 | 2026-06-15 |
| SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS Multimodal Prehabilitation - Advanced Ovarian Cancer | Not applicable | Completed | Hospital Clinic of Barcelona | 158 | 2021-04-20 | 2026-08-06 |
| Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer SC10914 - Advanced Ovarian Cancer | Phase 2 | Unknown | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 104 | 2020-12-15 | 2021-05-12 |
| The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Ropivacaine, Saline Solution - Advanced Ovarian Cancer | Phase 3 | Active not recruiting | Karolinska Institutet | 220 | 2020-08-27 | 2026-09-28 |
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer Tranexamic Acid, normal saline - Advanced Ovarian Cancer | Not applicable | Completed | Jun Zhang | 151 | 2020-06-03 | 2022-06-01 |
| Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer Intraperitoneal chemotherapy - Advanced Ovarian Cancer | Completed | Far Eastern Memorial Hospital | 50 | 2019-10-28 | 2020-06-29 | |
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer 2X-121 - Advanced Ovarian Cancer | Phase 2 | Recruiting | Allarity Therapeutics | 40 | 2019-04-15 | 2025-08-28 |
| Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Bevacizumab, Durvalumab, Olaparib - Advanced Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1407 | 2019-01-04 | 2026-07-07 |
| Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Bevacizumab - Advanced Ovarian Cancer | Phase 2 | Unknown | Nada Hassan Salah | 40 | 2018-09-01 | 2018-08-02 |
Showing 20 of 28. Sign in to see all of them.
Ovarian Neoplasms (4) · Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · COVID-19 (1) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Malaria, Vivax (1) · Melanoma (1) · Motor Activity (1) · Pathologic Complete Response (1) · Postoperative Complications (1) · Stomach Neoplasms (1)
Neoplasms by Site (8) · Neoplasms (7) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Gonadal Disorders (4) · Ovarian Diseases (4) · Skin Diseases (4)
olaparib (4) · Bevacizumab (3) · Carboplatin (3) · Paclitaxel (3) · Saline Solution (3) · CP protocol (2) · 1-dodecylpyridoxal (1) · Antineoplastic Agents (1) · Cyclophosphamide (1) · Drug Evaluation (1) · Fulvestrant (1) · Gemcitabine (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Interleukin-2 (1) · Neoadjuvant Therapy (1)
AstraZeneca (4) · Allarity Therapeutics (1) · Anhui Provincial Hospital (1) · Asan Medical Center (1) · Aston Sci. Inc. (1) · Azienda USL Reggio Emilia - IRCCS (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Bristol-Myers Squibb (1) · CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Daiichi Sankyo (1) · Epsilogen Ltd (1) · Far Eastern Memorial Hospital (1) · Fudan University (1) · Grupo Español de Investigación en Cáncer de Ovario (1)
United States (9) · China (8) · Canada (4) · Spain (4) · United Kingdom (4) · Brazil (3) · Denmark (3) · Italy (3) · Japan (3) · South Korea (3) · Australia (2) · Belgium (2) · France (2) · Netherlands (2) · Poland (2)
Alice P Chen, M.D. (1) · Berta Diaz-Feijoo, MD PHD (1) · Carol Aghajanian (1) · Dr Johann de Bono, MD (1) · Giorgio Senaldi, MD, PhD (1) · Guo Shuiqun, Ph.D., M.D. (1) · Hun Jung, MD, PhD (1) · Jane Robertson, BSc, MBCHB, MD (1) · Jun Zhang, PhD (1) · M Jose Arguis, MD (1) · Marcus Butler, M.D. (1) · Philipp Harter (1) · Prof Jan HM Schellens (1)
PMID 22248721, PMID 24428857, PMID 26801659, PMID 30345884, PMID 30792217, PMID 31637669, PMID 31667659, PMID 31865770, PMID 32224739, PMID 33862001, PMID 34329939, PMID 34715071, PMID 35170751, PMID 35793862, PMID 36082969, PMID 37029431, PMID 37185961, PMID 38010394, PMID 39572271, PMID 39695768, PMID 40102759, PMID 40652770, PMID 40772525, PMID 40856042
2017 (2), 2016 (1), 2025 (1)